Business
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq L
About this update from Meiragtx Holdings Plc
[{"type":"image","alt":"MeiraGTx","displaySize":"","headline":null,"caption":"MeiraGTx","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/60ece5081b9af642a0dc8da28326e24c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eC4lbfkMlXttl7mRddmcYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgz/https://media.zenfs.com/en/globenewswire.com/60ece5081b9af642a0dc8da28326e24c","width":300,"height":59},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/eC4lbfkMlXttl7mRddmcYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgz/https://media.zenfs.com/en/globenewswire.com/60ece5081b9af642a0dc8da28326e24c","width":300,"height":59}},"lazy":false},{"type":"text","content":"LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).","length":523,"tagName":"p"},{"type":"text","content":"Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company’s ordinary shares with an exercise price equal to $9.97, 25% of which will vest and become exercisable on the first anniversary of Ms. Fleck’s start date, with the remaining underlying shares vesting in 36 substantially equal installments each month thereafter, subject to Ms. Fleck’s continued employment with the Company through each applicable vesting date and (ii) 100,000 time-based restricted stock units (“RSUs”), with 50% of the RSUs vesting on the second anniversary of Ms. Fleck’s start date and 25% of the RSUs vesting on each of the third and fourth anniversaries of Ms. Fleck’s start date, subject to Ms. Fleck’s continued employment with the Company through each applicable vesting date.","length":821,"tagName":"p"},{"type":"text","content":"About MeiraGTx ","length":14,"tagName":"p"},{"type":"text","content":"MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-...